Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More
CMB International: Maintains INNOVENT BIO's "Buy" rating, with the Target Price raised to 57.67 HKD.
CMB International has released a research report stating that it maintains a "Buy" rating for INNOVENT BIO (01801), being bullish on the global potential of INNOVENT's Innovative Drugs pipeline, and has raised the target price to HKD 57.67 (previous value: HKD 55.21; WACC: 9.5%, perpetual growth rate: 3.5%). The company has licensed the global rights of the new DLL3ADC (IBI3009) to Roche, receiving an upfront payment of USD 80 million and up to USD 1 billion in milestone payments and sales sharing. The drug is expected to receive IND approval for global Phase 1 research in December 2024. Regarding the DLL3 target, besides
Novartis' Gene Therapy Meets Primary Endpoint in SMA Study
Here's Why Novartis (NVS) Is a Strong Growth Stock
Top Gap Ups and Downs on Monday: AR, DJT, MSTR and More
Novartis Reports Positive Results for Intrathecal Zolgensma
Novartis Says Gene Therapy for Spinal Muscular Atrophy Meets Primary Endpoint in Phase 3 Study
Novartis AG (NVS.US): Its new experimental drug improves motor functions in children with SMA.
Novartis AG stated that their new experimental drug improved motor function in children with spinal muscular atrophy (SMA) in a late-stage study.
Reported Earlier, Novartis Reports Topline Results From Phase III STEER Study; Study Met Its Primary Endpoint
Novartis Experimental Medicine Shows Improvement in Spinal Muscular Atrophy
Novartis Says New Drug Helps Children With Rare Spinal Condition
Novartis' Late-stage Study for Spinal Muscular Atrophy Therapy Meets Primary Endpoint
Novartis AG (NVS): Among the Cheap Healthcare Stocks to Buy Heading Into 2025
Sector Update: Health Care
Novartis to Face Whistleblower Case on MS Drug Kickbacks: Report
Novartis Must Face Claims Alleging Kickbacks for MS Drug Promotion, US Appeals Court Rules
Novartis Must Face Claims Alleging Kickbacks for MS Drug Promotion, Appeals Court Rules
Top Gap Ups and Downs on Monday: TSM, HMC, GFI and More
Why Is Novartis AG (NVS) Among the Best European Dividend Stocks To Buy Now?
RAPT Rockets 180% on Licensing Deal, $150M Private Placement